logo
Forever 21 to close all NY stores amid bankruptcy filing

Forever 21 to close all NY stores amid bankruptcy filing

Yahoo19-03-2025

All Forever 21 stores, including those in New York, are set to close by May 1 as the retailer's operator filed its second bankruptcy in six years, USA TODAY reported.
F21 OpCo, the operator of Forever 21, announced the voluntary Chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware on Sunday and legal counsel for F21 OpCo said during a hearing on Tuesday that the company anticipates to vacate its approximately 354 leased stores by the end of April, a spokesperson for the fast fashion retailer told USA TODAY.
According to court records, the company plans to complete all store closing sales before May 1, with many closing before April 1. Once the closing sales are complete, the stores will close, the spokesperson noted.
"On behalf of the company, I'd like to express our deep appreciation for the hard work of our dedicated employees and their commitment to our customers," Brad Sell, chief financial officer of F21 OpCo, said in a news release. "We are also grateful for the many years of support from our partners and our loyal customers, who have allowed us to serve as a fashion industry leader and go-to retailer for generations.'
Here's what to know.
The chain, which sells trendy styles for young men and women at low prices, has struggled to compete with Chinese online discount sites Shein and Temu.
Jamie Salter, the CEO of Authentic Brands, the fast fashion retailer's brand and intellectual property owner, spoke during a conference last year and said Forever 21's partnership with Shein, which came to be in 2023, only yielded modest results, according to Retail Dive.
Salter said before Authentic Brands and mall owners, Simon Property Group and Brookfield Corporation, saved Forever 21 from bankruptcy five years ago, he "didn't see Shein" and "didn't see Temu," per Retail Dive. The CEO added that he and his partners decided to partner with Shein because their "supply chain is too good" and they knew they could not "beat them."
Sell, the CFO of F21 OpCo, said foreign fast fashion companies take advantage of the de minimis exemption, which allows shipments of items valued at or under $800 to enter the U.S. duty-free and with very little paperwork. This exemption helps Chinese online retailers, such as Shein and Temu, keep clothing prices markedly low.
President Donald Trump halted his administration's repeal of the exemption in February after the rapid change created disruptions for customs inspectors, postal and delivery services and online retailers.
According to the bankruptcy court filing from March 17, all 21 stores in New York are being considered for closure. The move is pending court approval. Here's which New York locations are on the list:
Staten Island: Staten Island Mall, 2655 Richmond Ave., Suite 1040
Valley Stream: Green Acres Mall, 2034 Green Acres Mall, Space #108
Bayshore: South Shore Mall, 1701 Sunrise Highway, #D10
West Nyack: Palisades Center, 3510 Palisades Center Drive, Suite G307
Victor: Eastview Mall, 7979 Pittsford-Victor Road, Suite #140
Poughkeepsie: Poughkeepsie Galleria, 2001 South Road, #181
Yorktown Heights: Jefferson Valley Mall, 650 Lee Blvd., #D118
Middletown: Galleria at Crystal Run, 1 Galleria Drive, Space #D207
Glendale: The Shops at Atlas Park, 80-40 Cooper Ave., Suite #4-002
Niagara Falls: Fashion Outlets of Niagara Falls, 1965 Fashion Blvd., Suite 238
Riverhead: Tanger Outlets Riverhead, 200 Tanger Mall Drive, Suite 201
Lake Grove: Smith Haven Mall, 313 Smith Haven Mall, Space #M05
Yonkers: Cross Country Center, 8040 Mall Walk
Brooklyn: Kings Plaza Shopping Center, 5301 Kings Plaza, #210
Garden City: Roosevelt Field, 630 Old Country Road
Deer Park: Tanger Outlets Deer Park, 152 The Arches Circle, Suite 924
New York City: Seventh Avenue — Penn Station, 435 Seventh Ave.
Central Valley: Woodbury Premium Outlets, 223 Red Apple Court, Space #0223
White Plains: The Westchester, 125 Westchester Ave.
Buffalo: Walden Galleria, 1 Walden Galleria, #TH110
New York City: Times Square, 1540 Broadway
Forever 21 closure: Store specializing trendy, thrifty fashions is closing at Eastview Mall
Forever 21's operator will look for a buyer of the retailer's assets, but until then, its stores will remain open and business will commence as usual, USA TODAY reported. To pay employees, the operator said it filed motions with the court that will allow them to use cash collateral for wages and benefits.
Forever 21 stores being in malls across the U.S. past May will depend on whether F21 OpCo can find a buyer. Although the Forever 21 stores may be closing, Authentic Brands owns the retailer's brand and plans to continue evolving the business.
"Forever 21 is one of the most recognizable names in fast fashion. It is a global brand rooted in the U.S. with a strong future ahead. Retail is changing, and like many brands, Forever 21 is adapting to create the right balance across stores, e-commerce and wholesale," Jarrod Weber, global president for lifestyle at Authentic Brands, told USA TODAY in a statement on Monday.
Weber said that the company's "licensee's decision to restructure its operations does not impact Forever 21's intellectual property or its international business."
"It presents an opportunity to accelerate the modernization of the brand's distribution model, setting it up to compete and lead in fast fashion for decades to come," he said.
See the list: Joann auctioning all NY store leases amid bankruptcy
Yes, for a short period.
Forever 21 plans to take gift cards for the first 30 days of its bankruptcy, according to bankruptcy court documents, which will be through April 15.
Contributing: Mississippi Clarion Ledger reporter Bonnie Bolden and USA Today Network
Emily Barnes reports on consumer-related issues for the USA TODAY Network's New York Connect Team, focusing on scam and recall-related topics. Follow her on X and Instagram @byemilybarnes. Get in touch at ebarnes@gannett.com.
This article originally appeared on Rochester Democrat and Chronicle: Forever 21 to close all NY stores amid bankruptcy filing

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FAW Toyota launches new bZ5 electric SUV
FAW Toyota launches new bZ5 electric SUV

Yahoo

time35 minutes ago

  • Yahoo

FAW Toyota launches new bZ5 electric SUV

FAW Toyota Motor Company, one of Toyota's main Chinese joint ventures, officially launched its new competitively-priced bZ5 battery-powered SUV on the local market, as the Japanese automaker looks to strengthen its foothold in China's fast-expanding new energy vehicle (NEV) market. The new bZ5 is available initially in four main variants, the 550 Joy, 550 Pro, 550 Pro Smart Drive and the 630 Pro, offering varying levels of equipment and trim, and with prices ranging between CNY 129,800 and CNY 159,800 yuan (US$ 18,100-US$ 22,300), inclusive of manufacturer incentives. The bZ5 550 models are powered by 200 kW motors, with their standard battery pack offering a maximum range of 550 km on a single charge. The come with features such as 16-inch central touchscreen, 5G connectivity, and AI-powered voice control. The 630 Pro model has an extended range of 630 km. The bZ5 range is designed to compete with the Tesla Model Y, China's best-selling battery-powered SUV, and is priced significantly lower than the Model Y's starting price of CNY263,500 while offering a similar range. "FAW Toyota launches new bZ5 electric SUV" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

BYD Introduces Most Affordable EV Model in the United Kingdom
BYD Introduces Most Affordable EV Model in the United Kingdom

Yahoo

time35 minutes ago

  • Yahoo

BYD Introduces Most Affordable EV Model in the United Kingdom

BYD Company Limited BYDDY, an EV manufacturer in China, has introduced its most affordable model in the United Kingdom as part of its broader strategy to surpass Tesla as the world's leading electric vehicle manufacturer. The newly launched Dolphin Surf is the European version of BYD's top-selling Chinese model, the Seagull, which recently saw its price drop to just $7,800 in China following further the China Automobile Manufacturers Association didn't name BYD directly, it recently cautioned that ongoing price reductions are fueling fears of a renewed price war in the Chinese EV market. BYD's Dolphin Surf, priced from around $25,000, appears to be extending that pricing pressure into the United Kingdom, BYD outpaced Tesla in monthly vehicle registrations last month, selling 3,025 vehicles compared to Tesla's 2,016 units, and is on track to challenge Tesla's full-year performance. In April, BYD also overtook Tesla in European registrations for the first time, even before the Dolphin Surf entered the the UK's least expensive EV is the Dacia Spring, starting at $20,000 with a WLTP range of 140 miles. BYD's base Dolphin Surf 'Active' variant offers a 203-mile range, while the 'Boost' version extends that to 305 miles and starts at $30,000. Both models come equipped with premium features, such as a 10.1-inch rotatable touchscreen and smart driving functions. Although EVs already tend to be cheaper to own than petrol cars, the emergence of compact, low-cost EVs is seen as key to attracting more budget-conscious buyers. BYD's rapid growth in Europe continues despite the European Union imposing 17.4% tariffs on its vehicles due to concerns over Chinese government subsidies. The United Kingdom, however, has not imposed such tariffs, making it an attractive and increasingly important market for BYD. BYD has a Zacks Rank #5 (Strong Sell) at better-ranked stocks in the auto space are CarGurus, Inc. CARG, Strattec Security Corporation STRT and Michelin MGDDY, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today's Zacks #1 Rank stocks Zacks Consensus Estimate for CARG's 2025 sales and earnings implies year-over-year growth of 4.96% and 25%, respectively. EPS estimates for 2025 and 2026 have improved 30 cents and 44 cents, respectively, in the past 60 Zacks Consensus Estimate for STRT's fiscal 2025 sales and earnings implies year-over-year growth of 3.49% and 8.11%, respectively. EPS estimates for fiscal 2025 and 2026 have improved 73 cents and 91 cents, respectively, in the past 60 Zacks Consensus Estimate for MGDDY's 2025 sales and earnings implies year-over-year growth of 1.69% and 37.76%, respectively. EPS estimates for 2025 have improved a penny in the past 30 days. EPS estimates for 2025 have improved 3 cents in the past seven days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Strattec Security Corporation (STRT) : Free Stock Analysis Report Michelin (MGDDY) : Free Stock Analysis Report CarGurus, Inc. (CARG) : Free Stock Analysis Report Byd Co., Ltd. (BYDDY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

Yahoo

timean hour ago

  • Yahoo

Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China

SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store